Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 8/20 | 0.67 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165812 | 0.82 | CHRNB4 (0.87) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL895500 | 0.80 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7RAB9AMAPT | |
| SCHEMBL6797483 | 0.79 | CHRNB4 (0.96) | CHRNB4CHRNA3CHRNA7RAB9AMAPT | |
| SCHEMBL1068403 | 0.77 | — | — | |
| SCHEMBL22482394 | 0.74 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL24367106 | 0.70 | CHRNB4 (0.42) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL25319908 | 0.69 | CHRNB4 (0.46) | CHRNB4CHRNA3NPC1RAB9AMAPK1 | |
| SCHEMBL25319906 | 0.69 | CHRNB4 (0.46) | CHRNB4CHRNA3NPC1RAB9AMAPK1 | |
| SCHEMBL2282129 | 0.69 | NISCH (0.44) | CHRNB4CHRNA3NPC1RAB9AMAPK1 | |
| SCHEMBL14287876 | 0.69 | AXL (0.46) | CHRNB4CHRNA3NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180296532-A1 | RNA-Focused Small Molecules for Inhibiting RNA Toxicity in Myotonic Dystrophy | SCRIPPS RESEARCH INST (US) | 2018-10-18 | — | — | US | disclosed |
| US-10098902-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | CHRNB4 3020/4885CHRNA3 2163/4885CHRNA7 1749/4885 |
| US-20180296532-A1 | RNA-Focused Small Molecules for Inhibiting RNA Toxicity in Myotonic Dystrophy | NSUN3, EMG1, RBM3 | CHRNB4 2395/4885CHRNA3 2257/4885CHRNA7 2972/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | CDK2, CCNA1, CDK1 | CHRNB4 4372/4885CHRNA3 4163/4885CHRNA7 4044/4885 |
| US-10098902-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | CHRNB4 3020/4885CHRNA3 2163/4885CHRNA7 1749/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | CHRNB4 3003/4885CHRNA3 2610/4885CHRNA7 2789/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | CHRNB4 3020/4885CHRNA3 2163/4885CHRNA7 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.